9/124280

```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1813nxm
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17   The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06   Engineering Information Encompass files have new names
 NEWS  4  Feb 16   TOXLINE no longer being updated
 NEWS  5  Apr 23   Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23   PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS  7  May 07   DGENE Reload
 NEWS  8  Jun 20   Published patent applications (A1) are now in USPATFULL
 NEWS  9  JUL 13   New SDI alert frequency now available in Derwent's
                   DWPI and DPCI

 NEWS EXPRESS  July 11 CURRENT WINDOWS VERSION IS V6.0b,
               CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
               AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001

=> file embase medline biosis uspatfull japio wpids caplus agricola lifesci
biotechds jicst-eplus

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.15       0.15

FILE 'EMBASE' ENTERED AT 12:04:22 ON 09 AUG 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:04:22 ON 09 AUG 2001

FILE 'BIOSIS' ENTERED AT 12:04:22 ON 09 AUG 2001
```

```
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 12:04:22 ON 09 AUG 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 12:04:22 ON 09 AUG 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 12:04:22 ON 09 AUG 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 12:04:22 ON 09 AUG 2001

FILE 'LIFESCI' ENTERED AT 12:04:22 ON 09 AUG 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)


FILE 'BIOTECHDS' ENTERED AT 12:04:22 ON 09 AUG 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

=> e porro  massimo/au

E1          11     PORRMANN VOLKER/AU
E2           1     PORRO/AU
E3           0 --> PORRO  MASSIMO/AU
E4          96     PORRO A/AU
E5           3     PORRO A D/AU
E6          11     PORRO A M/AU
E7           1     PORRO A R/AU
E8           1     PORRO A ROBERT/AU
E9           2     PORRO ABDO Y/AU
E10          1     PORRO ADALBERTO/AU
E11         12     PORRO ADOLFO/AU
E12          1     PORRO ADOLPHO/AU

=> e porro massimo/au

E1           1     PORRO MARIANO/AU
E2           1     PORRO MARIO/AU
E3          40 --> PORRO MASSIMO/AU
E4           2     PORRO MIGUEL E/AU
E5           9     PORRO MONICA/AU
E6           1     PORRO N/AU
E7           1     PORRO NICHOLAS D/AU
E8           1     PORRO NOEL M/AU
E9           7     PORRO NOVO N/AU
E10          7     PORRO P/AU
E11          1     PORRO PAOLO/AU
E12         13     PORRO R/AU

=> s e3

L1          40 "PORRO MASSIMO"/AU

=> s l1 and bacteria

L2          20 L1 AND BACTERIA
```

=> dup rem l2

PROCESSING COMPLETED FOR L2
L3 17 DUP REM L2 (3 DUPLICATES REMOVED)

=> d bib ab 1-17

L3 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 2000:84285 CAPLUS
DN 132:136410
TI Vaccines for prevention of gram-negative bacterial infections and endotoxin-related diseases
IN **Porro, Massimo**
PA Biosynth S.R.L., Italy
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 976402	A2	20000202	EP 1999-202476	19990727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US 1998-124280		19980729		

AB A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepd. by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.

L3 ANSWER 2 OF 17 USPATFULL
AN 1998:138863 USPATFULL
TI Potentiation of antibiotics
IN **Porro, Massimo**, Siena, Italy
Varra, Martti, Haartmaninkatu, Finland
PA BiosYnth S.r.l., Italy (non-U.S. corporation)
PI US 5834430 19981110
AI US 1995-456112 19950531 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with methods of potentiating an antibiotic. The invention also includes compositions of an antibiotic and a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a

minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions have potentiated antibiotic activity.

L3 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 1998:344326 CAPLUS
DN 129:27010
TI Combined use of anti-endotoxin synthetic peptides and of anti-endotoxin antibodies for the prophylaxis and treatment of endotoxicosis and septic shock
IN **Porro, Massimo**
PA Biosynth S.r.l., Italy
SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 842666	A2	19980520	EP 1997-203526	19971112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI IT 1996-MI2354		19961113		

AB Methods and compns. for neutralizing endotoxin and for the prophylaxis and treatment of endotoxicosis and septic shock are disclosed, which comprise the use of peptides specifically binding to the conserved endotoxin structure (Lipid A), and antibodies specifically binding to the antigenic determinants in the endotoxin core structure of different genera of Gram-neg. **bacteria**.

L3 ANSWER 4 OF 17 USPATFULL
AN 97:66100 USPATFULL
TI Peptides for neutralizing the toxicity of Lipid A
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5652211 19970729
AI US 1993-97830 19930726 (8)
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned , said Ser. No. US -49871 which is a continuation of Ser. No. US -658744
DT Utility
FS Granted
EXNAM Primary Examiner: Russell, Jeffrey E.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 39
ECL Exemplary Claim: 36,38
DRWN No Drawings
LN.CNT 683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which Is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L3 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 1997:117658 CAPLUS
DN 126:141909
TI Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric **bacteria**. [Erratum to document cited in CA125:163069]
AU Vaara, Martti; **Porro, Massimo**
CS Dep. Bacteriology Immunology, Univ. Helsinki, Helsinki, 00014, Finland
SO Antimicrob. Agents Chemother. (1997), 41(2), 496
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB The synthetic peptide KFFKFFKFF should read KFFKFFKFFK, and IKFLKFLKFL should read OKFLKFLKFLK. The index entries were cor.

L3 ANSWER 6 OF 17 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino

acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L3 ANSWER 7 OF 17 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 1
AN 1996:433941 BIOSIS
DN PREV199699147547
TI Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric **bacteria**.
AU Vaara, Martti (1); **Porro, Massimo**
CS (1) Dep. Bacteriol. and Immunol., P.O. Box 21, Univ. Helsinki, 00014 Helsinki Finland
SO Antimicrobial Agents and Chemotherapy, (1996) Vol. 40, No. 8, pp. 1801-1805.
ISSN: 0066-4804.
DT Article
LA English
AB A synthetic peptide, KFFKFFKFF, consisting of cationic lysine residues and hydrophobic phenylalanine residues was found to sensitize gram-negative **bacteria** to hydrophobic and amphipathic antibiotics. At a concentration of 3 mu-g/ml, it decreased the MIC of rifampin for smooth, encapsulated Escherichia coli by a factor of 300. Other susceptible bacterial species included Enterobacter cloacae, Klebsiella pneumoniae, and Salmonella typhimurium, but Pseudomonas aeruginosa was resistant. Similar results were obtained with another synthetic peptide, IKFLKFLKFL. The fractional inhibitory concentration indices for the synergism of these peptides with rifampin, erythromycin, fusidic acid, and novobiocin were very close to those determined for the previously characterized potent outer-membrane-disorganizing agents polymyxin B nonapeptide and deacylpolymyxin B. KFFKFFKFF had direct activity against the gram-positive organism Micrococcus strain ML36, was strongly hemolytic, and was as active on polymyxin-resistant E. coli mutants as on their parent. These three attributes made KFFKFFKFF different from polymyxin derivatives and similar to cationic detergents, such as cetylpyridinium chloride. However, whereas the MIC of cetylpyridinium chloride for E. coli is low (0.5 to 4 mu-g/ml), that of KFFKFFKFF is much higher (30 to 100 mu-g/ml). Other groups of synthetic peptides studied included polymyxin-like peptides with an intrachain disulfide bridge. Their synergism with antibiotics was less marked. Still other peptides, including K-EKEKEKEKE and KKKKKKFLFL, lacked any synergism with the probe antibiotics.

L3 ANSWER 8 OF 17 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11

ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel peptides of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L3 ANSWER 9 OF 17 USPATFULL
AN 94:93312 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5358933 19941025
AI US 1993-49871 19930419 (8)
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L3 ANSWER 10 OF 17 USPATFULL
AN 94:35369 USPATFULL
TI Oligosaccharide conjugate vaccines
IN **Porro, Massimo**, Siena, Italy
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5306492 19940426
AI US 1992-921678 19920730 (7)
RLI Division of Ser. No. US 1990-590649, filed on 28 Sep 1990, now patented, Pat. No. US 5153312
DT Utility
FS Granted
EXNAM Primary Examiner: Kim, Kay K.
LREP Dow, Kenneth J.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the

invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide.

A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.

L3 ANSWER 11 OF 17 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1994:423370 BIOSIS
DN PREV199497436370
TI Molecular requirements of peptide structure binding to the lipid-A region of bacterial endotoxins.
AU Velucchi, Massimo; Rustici, Alessandro; **Porro, Massimo**
CS Biosynth Res. Lab., Zona Industriale, Rapolano Terme, Siena 53040 Italy
SO Norrby, E. [Editor]; Brown, F. [Editor]; Chanock, R. M. [Editor]; Ginsberg, H. S. [Editor]. Vaccines (Cold Spring Harbor), (1994) Vol. 94, pp. 141-146. Vaccines (Cold Spring Harbor); Modern approaches to new vaccines including prevention of AIDS.
Publisher: Cold Spring Harbor Laboratory Press 10 Skyline Drive, Plainview, New York 11803, USA.
Meeting Info.: Eleventh Annual Meeting on Modern Approaches to New Vaccines Cold Spring Harbor, New York, USA September 1993
ISSN: 0899-4056. ISBN: 0-87969-434-3.
DT Book; Conference
LA English

L3 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 1994:698634 CAPLUS
DN 121:298634
TI Molecular requirements of peptide structures binding to the lipid-A region of bacterial endotoxins
AU Velucchi, Massimo; Rustici, Alessandro; **Porro, Massimo**
CS BioYnth Res. Lab., Zona Industriale, Siena, 53040, Italy
SO Vaccines 94: Mod. Approaches New Vaccines Incl. Prev. AIDS, [Annu. Meet.], 11th (1994), Meeting Date 1993, 141-6. Editor(s): Norrby, Erling.
Publisher: Cold Spring Harbor Lab. Press, Cold Spring Harboy, N.Y.
CODEN: 60PMAJ
DT Conference
LA English
AB The binding of selected peptides to lipid A of heterologous lipopolysaccharides was assessed and measured by the value of selectivity, which expresses the ratio between the affinity const. value of Polymyxin B and that of each synthetic peptide in competition anal. Both the ref. and the synthetic peptides with a value of .gtoreq.0.75 Rc/h were able to inhibit competitively the lipid A-induced hemorrhagic necrosis in rabbits at doses as high as 75-125 .mu.g/mL of LPS.

L3 ANSWER 13 OF 17 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2
AN 1993:145833 BIOSIS
DN PREV199395078633
TI Molecular mapping and detoxification of the lipid A binding site by synthetic peptides.
AU Rustici, Alessandro; Velucchi, Massimo; Faggioni, Raffaella; Sironi, Marina; Ghezzi, Pietro; Quataert, Sally; Green, Bruce; **Porro, Massimo (1)**
CS (1) Biosynth Res. Lab., Rapolano Terme, Siena, Italy 53040
SO Science (Washington D C), (1993) Vol. 259, No. 5093, pp. 361-365.
ISSN: 0036-8075.
DT Article
LA English
AB Endotoxin (lipopolysaccharide (LPS)), the major antigen of the outer

membrane of Gram-negative **bacteria**, consists of a variable-size carbohydrate chain that is covalently linked to N, O-acylated beta-1, 6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of LPS residues in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxity LPS in vitro, and prevent LPS-induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy of prophylaxis and the treatment of LPS-mediated diseases.

L3 ANSWER 14 OF 17 USPATFULL
AN 92:82892 USPATFULL
TI Oligosaccharide conjugate vaccines
IN **Porro, Massimo**, Siena, Italy
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5153312 19921006
AI US 1990-590649 19900928 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Kim, Kay
LREP Dow, Kenneth J.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide.
A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.

L3 ANSWER 15 OF 17 USPATFULL
AN 87:84425 USPATFULL
TI Glycoproteinic conjugates having trivalent immunogenic activity
IN **Porro, Massimo**, Localita' Collanza, Italy
Costantino, Paolo, Colle Val d'Elsa, Italy
PA Sclavo S.p.A., Siena, Italy (non-U.S. corporation)
PI US 4711779 19871208
AI US 1986-881091 19860702 (6)
PRAI IT 1985-21451 19850705
DT Utility
FS Granted
EXNAM Primary Examiner: Schain, Howard E.
LREP Hedman, Gibson, Costigan & Hoare
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 622
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Glycoproteinic conjugates having trivalent immunogenic activity obtained by binding, by a covalent bond, to a protein selected among CRM 197, tetanus toxoid, and pertussis toxin, at least an oligosaccharidic hapten derived from the capsular polysaccharide of a gram-positive bacterium and at least an oligosaccharidic hapten derived from the capsular polysaccharide of a gram-negative bacterium, and wherein said oligosaccharidic haptens are previously activated by introducing terminal esters.

L3 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2001 ACS

AN 1987:125868 CAPLUS
DN 106:125868
TI Prepn. of glycoproteinic conjugates having trivalent immunogenic activity as vaccines against bacterial infections
IN **Porro, Massimo**; Costantino, Paolo
PA Sclavo S.p.A., Italy
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 208375	A2	19870114	EP 1986-201160	19860702
	EP 208375	A3	19890405		
	EP 208375	B1	19911211		
	R: AT, BE, CH, DE, FR, GB, LI, LU, NL, SE				
	US 4711779	A	19871208	US 1986-881091	19860702
	AT 70187	E	19911215	AT 1986-201160	19860702
	JP 62030726	A2	19870209	JP 1986-156342	19860704
	CA 1272952	A1	19900821	CA 1986-513124	19860704
PRAI	IT 1985-21451		19850705		
	EP 1986-201160		19860702		

AB Glycoproteinic conjugates having trivalent immunogenic activity are prepd. by conjugating a protein (e.g. CRM 197) to .gtoreq.1 oligosaccharidic hapten(s) derived from the capsular polysaccharide of a gram-pos. bacterium and .gtoreq.1 oligosaccharidic hapten(s) derived from the capsular polysaccharide of a gram-neg. bacterium, where the oligosaccharidic haptens are previously activated by introducing terminal esters. Oligosaccharidic haptens were prepd. from the capsular polysaccharides of S. pneumoniae type 6A and N. meningitidis group C by hydrolysis reaction in pH 3.4 and 5, resp., at 100.degree. in a sealed ampul for 39 h and 8 h, resp. The haptens were activated by introducing primary amino groups into the terminal reducing groups of the haptens, and converting the amino groups to monofunctional esters in DMS contg. di-succinimidyl ester of adipic acid. The activated haptens were conjugated to CRM 197 protein. The antisera of rabbits injected with the conjugate showed bactericidal activity.

L3 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2001 ACS
AN 1986:205102 CAPLUS
DN 104:205102
TI A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated **bacteria**
AU **Porro, Massimo**; Costantino, Paolo; Giovannoni, Franco; Pellegrini, Vittoria; Tagliaferri, Lucia; Vannozzi, Francesca; Viti, Stefano
CS Bact. Vaccine Dep., Sclavo SpA, Siena, 53100, Italy
SO Mol. Immunol. (1986), 23(4), 385-91
CODEN: MOIMD5; ISSN: 0161-5890
DT Journal
LA English
AB An artificial mol. was synthesized by covalently linking the oligosaccharide hapten derived from Streptococcus pneumoniae type 6A and Neisseria meningitidis group C capsular polysaccharides to the non-toxic mutant protein CRM197, serol. related to diphtheria toxin. Immunochem. anal., using polyclonal and monoclonal antibodies, showed that the glycoprotein had specific immunodeterminants of the native polysaccharides and of the carrier protein. The immunol. activity of this hybrid mol. tested in 2 animal models gave evidence for anamnestic induction of serum antibodies specifically directed to the 3 distinct native mols. They

neutralized the toxicity of diphtheria toxin, recognized the polysaccharide capsule of S. pneumoniae type 6A and 6B (group 6) strain and killed the N. meningitidis group C **bacteria** by complement-mediated bacterial lysis. These findings support the possibility of using in humans a multivalent antigen with immunogenic activity for several epidemiol. significant gram-pos. and gram-neg. encapsulated bacterial strains.

=> d his

(FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA,
LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001
E PORRO MASSIMO/AU
E PORRO MASSIMO/AU
L1 40 S E3
L2 20 S L1 AND BACTERIA
L3 17 DUP REM L2 (3 DUPLICATES REMOVED)

=> s l1 and gram negative

L4 17 L1 AND GRAM NEGATIVE

=> s l4 and lps

L5 8 L4 AND LPS

=> d bib ab 1-8

L5 ANSWER 1 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
AN 2000:173998 BIOSIS
DN PREV200000173998
TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide (**LPS**) recognition and **LPS**-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.
AU Iwagaki, Akitaka; **Porro, Massimo**; Pollack, Matthew (1)
CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA
SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.
DT Article
LA English
SL English
AB Lipopolysaccharides (**LPS**) are proinflammatory bacterial products implicated in the pathogenesis of **gram-negative** sepsis and septic shock. Polymyxin B (PMB), a cyclic, cationic peptide antibiotic, inhibits biological activities of **LPS** through high-affinity binding to the lipid A moiety. Small synthetic peptides have been designed to mimic the primary and secondary structures of PMB to determine structural requirements for binding and detoxification of lipid A and to assess possible therapeutic potential. The purpose of this study was to compare and contrast the endotoxin-neutralizing activities of two synthetic antiendotoxin peptides (SAEP-2 and SAEP-4), PMB, and an **LPS** core-specific monoclonal antibody (MAb), WN1 222-5, based on their abilities to inhibit CD14-mediated target cell uptake of fluorescein isothiocyanate (FITC)-conjugated **LPS**, detected by flow cytometry

and confocal microscopy, and **LPS**-induced production of the proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), as measured by bioassays. PMB and SAEP-4 produced dose-dependent inhibition of FITC-**LPS** uptake by CD14-transfected Chinese hamster ovary fibroblasts (CHO-CD14 cells) and by human peripheral blood mononuclear cells. The anti-**LPS** MAb, WN1 222-5, also blocked **LPS** uptake by these cells and synergized with PMB and SAEP-4. **LPS**-induced IL-6 release was inhibited by PMB, SAEP-4, and MAb WN1 222-5, and these inhibitory activities were additive or synergistic. **LPS**-induced TNF-alpha release by PBMC was also inhibited by PMB and SAEP-4 alone and in combination with anti-**LPS** MAb. SAEP-2, in contrast, produced comparatively minor decrements in cellular uptake of **LPS** and **LPS**-induced cytokine responses, and did so only in the absence of serum, while a nonsense peptide exerted no discernible inhibitory effect on **LPS** uptake or **LPS**-induced cytokine expression in the presence or absence of serum. Thus, PMB and SAEP-4, like the **LPS**-reactive MAb, WN1 222-5, block proinflammatory activities of **LPS** in part by preventing **LPS** recognition by membrane-bound CD14-expressing target cells. Differences in peptide structure, however, like those exemplified by SAEP-2 and SAEP-4, may differentially affect the endotoxin-neutralizing potency of these peptides despite similar binding activity against lipid A, reflecting possible differences in peptide solubility or peptide regulation of intracellular signal transduction.

L5 ANSWER 2 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1993:145833 BIOSIS
DN PREV199395078633
TI Molecular mapping and detoxification of the lipid A binding site by synthetic peptides.
AU Rustici, Alessandro; Velucchi, Massimo; Faggioni, Raffaella; Sironi, Marina; Ghezzi, Pietro; Quataert, Sally; Green, Bruce; **Porro, Massimo (1)**
CS (1) Biosynth Res. Lab., Rapolano Terme, Siena, Italy 53040
SO Science (Washington D C), (1993) Vol. 259, No. 5093, pp. 361-365. ISSN: 0036-8075.
DT Article
LA English
AB Endotoxin (lipopolysaccharide (**LPS**)), the major antigen of the outer membrane of **Gram-negative** bacteria, consists of a variable-size carbohydrate chain that is covalently linked to N, 0-acylated beta-1, 6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of **LPS** residues in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxity **LPS** in vitro, and prevent **LPS** -induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy of prophylaxis and the treatment of **LPS**-mediated diseases.

L5 ANSWER 3 OF 8 USPATFULL
AN 1998:138863 USPATFULL
TI Potentiation of antibiotics
IN **Porro, Massimo**, Siena, Italy
Varra, Martti, Haartmaninkatu, Finland
PA BiosYnth S.r.l., Italy (non-U.S. corporation)
PI US 5834430 19981110
AI US 1995-456112 19950531 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 45

ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with methods of potentiating an antibiotic. The invention also includes compositions of an antibiotic and a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions have potentiated antibiotic activity.

L5 ANSWER 4 OF 8 USPATFULL
AN 97:66100 USPATFULL
TI Peptides for neutralizing the toxicity of Lipid A
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5652211 19970729
AI US 1993-97830 19930726 (8)
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned , said Ser. No. US -49871 which is a continuation of Ser. No. US -658744
DT Utility
FS Granted
EXNAM Primary Examiner: Russell, Jeffrey E.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 39
ECL Exemplary Claim: 36,38
DRWN No Drawings
LN.CNT 683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which Is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine,

Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L5 ANSWER 5 OF 8 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L5 ANSWER 6 OF 8 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel peptides of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the prevention

and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L5 ANSWER 7 OF 8 USPATFULL
AN 94:93312 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5358933 19941025
AI US 1993-49871 19930419 (8)
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2001 ACS
AN 2000:84285 CAPLUS
DN 132:136410
TI Vaccines for prevention of **gram-negative** bacterial infections and endotoxin-related diseases
IN **Porro, Massimo**
PA Biosynth S.R.L., Italy
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 976402	A2	20000202	EP 1999-202476	19990727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US 1998-124280		19980729		

AB A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepd. by combining **LPS** free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.

=> d clm 4 5 6 7

L5 ANSWER 4 OF 8 USPATFULL
CLM What is claimed is:
1. A peptide consisting of the formula: (Lys-Phe).sub.5 (SEQ ID NO: 5).

2. A peptide consisting of the formula: Lys-Phe-Leu-Lys-Lys-Thr-Leu (SEQ ID NO: 6).

3. A peptide consisting of the formula: (Lys-Phe-Phe).sub.3 -Lys (SEQ ID NO: 10).

4. A peptide consisting of the formula: (Lys-Leu-Leu).sub.3 (SEQ ID NO: 11).

5. A peptide consisting of the formula: (Lys).sub.6 (Phe-Lys).sub.2 (SEQ ID NO: 12).

6. A peptide consisting of the formula: ##STR13##

7. A peptide consisting of the formula: ##STR14##

8. A peptide consisting of the formula: ##STR15##

9. A peptide consisting of the formula: ##STR16##

10. A peptide consisting of the formula: ##STR17##

11. A peptide consisting of the formula: ##STR18##

12. A peptide consisting of the formula: ##STR19##

13. A peptide consisting of the formula:
Lys-Ser-Leu-Ser-Leu-Lys-Arg-Leu-
Thr-Tyr-Arg (SEQ ID NO:22).

14. A peptide consisting of the formula:
Lys-Val-Arg-Lys-Ser-Phe-Phe-Lys-
Leu (SEQ ID NO: 23).

15. A peptide consisting of the formula:
Phe-Leu-Lys-Pro-Gly-Lys-Val-Lys-
Val (SEQ ID NO: 24).

16. A peptide consisting of the formula:
Lys-Glu-Leu-Lys-Arg-Ile-Lys-Ile
(SEQ ID NO: 25).

17. A peptide consisting of the formula: ##STR20##

18. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 1.

19. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 2.

20. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 3.

21. A peptide composition which includes a pharmaceutical carrier and a

peptide of claim 4.

22. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 5.

23. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 6.

24. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 7.

25. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 8.

26. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 9.

27. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 10.

28. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 11.

29. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 12.

30. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 13.

31. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 14.

32. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 15.

33. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 16.

34. A peptide composition which includes a pharmaceutical carrier and a peptide consisting of the formula: Lys-Arg-Leu-Lys-Trp-Lys-Tyr-Lys-Gly-Lys-Phe (SEQ ID NO:28).

35. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 17.

36. A peptide composition which comprises a peptide of the formula (Lys).sub.30 (SEQ ID NO: 2) and a pharmaceutical carrier.

37. A peptide composition which comprises a peptide of the formula (Lys).sub.434 (SEQ ID NO: 3) and a pharmaceutical carrier.

38. A method of treating or preventing septic shock which comprises administering to a mammal an effective amount of the peptide composition of claim 36.

39. A method of treating or preventing septic shock which comprises administering to a mammal an effective amount of the peptide composition of claim 37.

L5 ANSWER 5 OF 8 USPATFULL
CLM What is claimed is:
1. A method for the removal of endotoxin from human and animal blood

sera which comprises contacting said blood or sera with a peptide of which is a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1 --(A--B--C).sub.n --R (I) wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100, in an amount which is effective for the removal of endotoxin from said blood or sera.

2. A method for the detoxification of bacterial endotoxins which comprises treating the affected host with an amount of a peptide which is a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1 --(A--B--C).sub.n --R (I) wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu Ile and Val; n is an integer of from 1-100 which is effective to detoxify any endotoxin which is in an affected host.

3. A method for the detoxification of a bacterial endotoxin which comprises contacting the bacterial endotoxin or a fluid containing the endotoxin with an amount of a peptide, which is effective for detoxification of said bacterial endotoxin, said peptide being a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1 --(A--B--C).sub.n --R (I) wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue.; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100.

4. A method for preventing contamination of a product with endotoxin, said method comprising adding to a product an amount of a peptide which is a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1 --(A--B--C).sub.n --R (I) wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100 which is effective to neutralize any endotoxin which is subsequently elaborated by bacterial growth.

5. A method as defined in claim 2 wherein the peptide is of the formula:

##STR3##

6. A method as defined in claim 2 wherein the peptide is of the formula:

##STR4##

7. A method as defined in, claim 2 wherein the peptide is of the formula: Lys-Phe-Leu-Lys-Lys-Thr (SEQ ID NO:3).

8. A method as defined in claim 2 wherein the peptide is of the formula:

##STR5##

9. A method as defined in claim 2 wherein the peptide is of the formula:
##STR6##

10. A method as defined in claim 2 wherein the peptide is of the formula: ##STR7##

11. A method as defined in claim 2 wherein the peptide is of the formula: Ile--Lys--Thr--Lys--Lys--Phe--Leu--Lys--Lys--Thr (SEQ ID NO:7).

12. A method as defined in claim 2 wherein the peptide is of the formula: Ile--Lys--Phe--Leu--Lys--Phe--Leu--Lys--Phe--Leu--Lys (SEQ ID NO:8).

13. A method as defined in claim 2 wherein the peptide is of the formula: Lys--Phe--Leu--Lys--Phe--Leu--Lys (SEQ ID NO:9).

14. A method as defined in claim 2 wherein the peptide is of the formula: Arg-Tyr-Val-Arg-Tyr-Val-Arg-Tyr-Val (SEQ ID NO:10).

L5 ANSWER 6 OF 8 USPATFULL
CLM What is claimed is:
1. A monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1 -(A-B-C).sub.n -R
(I) wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100.

2. A monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1 (Lys-Phe-Leu).sub.n -R
(II) wherein n is a integer of from 1-10 and R and R.sup.1 are H or an amino acid residue or a fatty acid residue.

3. A peptide which is of the formula: Lys-Phe-Leu-Lys-Phe-Leu-Lys (SEQ ID NO:9).

4. A peptide which is of the formula: Arg-Tyr-Val-Arg-Tyr-Val-Arg-Tyr-Val (SEQ ID NO.10).

5. A pharmaceutical composition which comprises a peptide of claim 1 and
a pharmaceutical carrier.

6. A pharmaceutical composition which comprises a peptide of claim 3 and
a pharmaceutical carrier.

7. A pharmaceutical composition which comprises a peptide of claim 4 and
a pharmaceutical carrier.

8. Peptide sequences which are the retro-oriented amino acid sequences of claim 1.

9. Peptide sequences which are the enantiomer amino acid sequences (all-D amino acid in the sequence) of the peptides of claim 1.

10. Peptide sequences which are the diastereomer amino acid sequences of the peptides of claim 1 (-D and -L amino acid in the same sequence).

11. Peptide sequences in which the amino acids are inverted with respect to their original position in the sequence of the peptides of claim 1.

L5 ANSWER 7 OF 8 USPATFULL
CLM What is claimed is:
1. A peptide of the formula: Cys-Lys-Phe-Leu-Lys-Lys-Cys S----------S (SEQ ID NO:1)

2. A peptide according to which is of the formula: Lys-Thr-Lys-Cys-Lys-Phe-Leu-Lys-Lys-Cys S----------S (SEQ ID NO:2)

3. A peptide which is of the formula: Lys-Phe-Leu-Lys-Lys-Thr (SEQ ID NO:3)

4. A peptide which is of the formula: Cys-Lys-Lys-Leu-Phe-Lys-Cys-Lys-Thr-Lys S----------S (SEQ ID NO:4)

5. A peptide which is of the formula: Cys-Lys-Lys-Leu-Phe-Lys-Cys-Lys-Thr S----------S(SEQ ID NO:5)

6. A peptide which is of the formula: Ile-Lys-Thr-Lys-Cys-Lys-Phe-Leu-Lys-Lys-Cys S----------S (SEQ ID NO:6)

7. A peptide which is of the formula: Ile-Lys-Thr-Lys-Lys-Phe-Leu-Lys-Lys-Thr (SEQ ID NO:7)

8. A peptide which is of the formula: Ile-Lys-Phe-Leu-Lys-Phe-Leu-Lys-Phe-Leu-Lys (SEQ ID NO:8)

9. A pharmaceutical composition which comprises a peptide of claim 1 and a pharmaceutical carrier.

10. A pharmaceutical composition which comprises a peptide of claim 2 and a pharmaceutical carrier.

11. A pharmaceutical composition which comprises a peptide of claim 3 and a pharmaceutical carrier.

12. A pharmaceutical composition which comprises a peptide of claim 4 and a pharmaceutical carrier.

13. A pharmaceutical composition which comprises a peptide of claim 5 and a pharmaceutical carrier.

14. A pharmaceutical composition which comprises a peptide of claim 6 and a pharmaceutical carrier.

15. A pharmaceutical composition which comprises a peptide of claim 7 and a pharmaceutical carrier.

16. A pharmaceutical composition which comprises a peptide of claim 8 and a pharmaceutical carrier.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001)

     FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS,
AGRICOLA,
     LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001
                E PORRO  MASSIMO/AU
                E PORRO MASSIMO/AU
L1            40 S E3
L2            20 S L1 AND BACTERIA
L3            17 DUP REM L2 (3 DUPLICATES REMOVED)
L4            17 S L1 AND GRAM NEGATIVE
L5             8 S L4 AND LPS

=> s l1 and lps

L6          14 L1 AND LPS

=> dup rem l6

PROCESSING COMPLETED FOR L6
L7            12 DUP REM L6 (2 DUPLICATES REMOVED)

=> d bib ab 1-12


L7   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2001 ACS
AN   2000:84285  CAPLUS
DN   132:136410
TI   Vaccines for prevention of gram-negative bacterial infections and
     endotoxin-related diseases
IN   Porro, Massimo
PA   Biosynth S.R.L., Italy
SO   Eur. Pat. Appl., 40 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   EP 976402           A2   20000202      EP 1999-202476   19990727
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
PRAI US 1998-124280          19980729
AB   A vaccine is disclosed which is useful for protecting a host from Gram
     neg. infections and the effects of endotoxin, therefore preventing sepsis
     and septic shock.  The vaccine is prepd. by combining LPS free
     or in conjugate form with a stoichiometric excess of a peptide of the
     formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer
with
     a min. value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a
     hydrophobic amino acid selected from the group consisting of Valine,
     Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an
     integer with a min. value of 3; and (c) (ABC)p wherein A is a cationic
     amino acid which is Lysine or Arginine; B and C are hydrophobic amino
     acids which may be the same or different and are selected from the group
     consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and
     Tryptophan; p is an integer with a min. value of 2.

L7   ANSWER 2 OF 12  BIOSIS  COPYRIGHT 2001 BIOSIS      DUPLICATE 1
AN   2000:173998  BIOSIS
DN   PREV200000173998
```

TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide (**LPS**) recognition and **LPS**-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.
AU Iwagaki, Akitaka; **Porro, Massimo**; Pollack, Matthew (1)
CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA
SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.
DT Article
LA English
SL English
AB Lipopolysaccharides (**LPS**) are proinflammatory bacterial products implicated in the pathogenesis of gram-negative sepsis and septic shock. Polymyxin B (PMB), a cyclic, cationic peptide antibiotic, inhibits biological activities of **LPS** through high-affinity binding to the lipid A moiety. Small synthetic peptides have been designed to mimic the primary and secondary structures of PMB to determine structural requirements for binding and detoxification of lipid A and to assess possible therapeutic potential. The purpose of this study was to compare and contrast the endotoxin-neutralizing activities of two synthetic antiendotoxin peptides (SAEP-2 and SAEP-4), PMB, and an **LPS** core-specific monoclonal antibody (MAb), WN1 222-5, based on their abilities to inhibit CD14-mediated target cell uptake of fluorescein isothiocyanate (FITC)-conjugated **LPS**, detected by flow cytometry and confocal microscopy, and **LPS**-induced production of the proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), as measured by bioassays. PMB and SAEP-4 produced dose-dependent inhibition of FITC-**LPS** uptake by CD14-transfected Chinese hamster ovary fibroblasts (CHO-CD14 cells) and by human peripheral blood mononuclear cells. The anti-**LPS** MAb, WN1 222-5, also blocked **LPS** uptake by these cells and synergized with PMB and SAEP-4. **LPS**-induced IL-6 release was inhibited by PMB, SAEP-4, and MAb WN1 222-5, and these inhibitory activities were additive or synergistic. **LPS**-induced TNF-alpha release by PBMC was also inhibited by PMB and SAEP-4 alone and in combination with anti-**LPS** MAb. SAEP-2, in contrast, produced comparatively minor decrements in cellular uptake of **LPS** and **LPS**-induced cytokine responses, and did so only in the absence of serum, while a nonsense peptide exerted no discernible inhibitory effect on **LPS** uptake or **LPS**-induced cytokine expression in the presence or absence of serum. Thus, PMB and SAEP-4, like the **LPS**-reactive MAb, WN1 222-5, block proinflammatory activities of **LPS** in part by preventing **LPS** recognition by membrane-bound CD14-expressing target cells. Differences in peptide structure, however, like those exemplified by SAEP-2 and SAEP-4, may differentially affect the endotoxin-neutralizing potency of these peptides despite similar binding activity against lipid A, reflecting possible differences in peptide solubility or peptide regulation of intracellular signal transduction.

L7 ANSWER 3 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS
AN 2000:532911 BIOSIS
DN PREV200000532911
TI Effects of synthetic anti-endotoxin peptides (SAEP) on calmodulin.
AU Rustici, Alessandro (1); Velucchi, Massimo (1); **Porro, Massimo (1)**
CS (1) BiosYnth Srl, 53040, Rapolano Terme, Siena Italy
SO Journal of Endotoxin Research, (2000) Vol. 6, No. 2, pp. 133-134. print. Meeting Info.: 6th Conference of the International Endotoxin Society Paris, France August 24-27, 2000
ISSN: 0968-0519.
DT Conference
LA English
SL English

L7 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2001 ACS
AN 1999:605922 CAPLUS
DN 132:20140
TI **LPS**/lipid A-binding synthetic peptides
AU **Porro, Massimo**
CS Biosynth Research Laboratories, Siena, Italy
SO Endotoxin Health Dis. (1999), 403-411. Editor(s): Brade, Helmut. Publisher: Marcel Dekker, New York, N. Y.
CODEN: 68EJA9
DT Conference; General Review
LA English
AB A review with 47 refs. on polymyxin B and its peptide analogs binding to lipid A.
RE.CNT 47
RE
(3) Bhattacharjya, S; Biopolymers 1997, V41(3), P251 CAPLUS
(4) Cady, A; Infect Immun 1989, V57, P396 CAPLUS
(5) Cho, H; J Exp Med 1992, V176, P599 CAPLUS
(6) Christensen, H; J Biol Chem 1966, V241, P5542 CAPLUS
(7) Craig, W; Infect Immun 1974, V10, P287 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 12 USPATFULL
AN 1998:138863 USPATFULL
TI Potentiation of antibiotics
IN **Porro, Massimo**, Siena, Italy
Varra, Martti, Haartmaninkatu, Finland
PA BiosYnth S.r.l., Italy (non-U.S. corporation)
PI US 5834430 19981110
AI US 1995-456112 19950531 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with methods of potentiating an antibiotic. The invention also includes compositions of an antibiotic and a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions have potentiated antibiotic activity.

L7 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2001 ACS

AN 1998:412126 CAPLUS
DN 129:188002
TI Natural and synthetic polypeptides that recognize the conserved lipid A binding site of lipopolysaccharides
AU **Porro, Massimo**; Rustici, Alessandro; Velucchi, Massimo; Agnello, Davide; Villa, Pia; Ghezzi, Pietro
CS Biosynth Research Laboratories, Siena, 53040, Italy
SO Prog. Clin. Biol. Res. (1998), 397(Endotoxin and Sepsis), 315-325
CODEN: PCBRD2; ISSN: 0361-7742
PB Wiley-Liss, Inc.
DT Journal; General Review
LA English
AB A review with .apprx.25 refs. The authors review their work on various natural and synthetic polypeptides that recognize the conserved lipid A binding site of lipopolysaccharides and in particular talk about in vivo and in vitro assays demonstrating the ability of nociceptin to neutralize lipopolysaccharide activity. The results suggest that nociceptin might be a potential target of **LPS** in the central and peripheral nervous system. Its capability to interact with **LPS**, through lipid A, might work as a recognition system alerting the host's defenses on the basis of an imbalance in the equil. nociceptin/nociceptor, therefore serving as a physiol. defense against the early biol. effects which follow an **LPS** insult.

L7 ANSWER 7 OF 12 USPATFULL
AN 97:66100 USPATFULL
TI Peptides for neutralizing the toxicity of Lipid A
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5652211 19970729
AI US 1993-97830 19930726 (8)
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned , said Ser. No. US -49871 which is a continuation of Ser. No. US -658744
DT Utility
FS Granted
EXNAM Primary Examiner: Russell, Jeffrey E.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 39
ECL Exemplary Claim: 36,38
DRWN No Drawings
LN.CNT 683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which Is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine,

Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with
a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L7 ANSWER 8 OF 12 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,
Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H
or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino
acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L7 ANSWER 9 OF 12 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel peptides of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the prevention

and/or treatment of septic shock, for the detection of endotoxin and the
preparation of antigenic complexes of Lipid A.

L7 ANSWER 10 OF 12 USPATFULL
AN 94:93312 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5358933 19941025
AI US 1993-49871 19930419 (8)
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino
acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L7 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2001 ACS
AN 1994:698634 CAPLUS
DN 121:298634
TI Molecular requirements of peptide structures binding to the lipid-A region
of bacterial endotoxins
AU Velucchi, Massimo; Rustici, Alessandro; **Porro, Massimo**
CS BioYnth Res. Lab., Zona Industriale, Siena, 53040, Italy
SO Vaccines 94: Mod. Approaches New Vaccines Incl. Prev. AIDS, [Annu. Meet.], 11th (1994), Meeting Date 1993, 141-6. Editor(s): Norrby, Erling.
Publisher: Cold Spring Harbor Lab. Press, Cold Spring Harboy, N.Y.
CODEN: 60PMAJ
DT Conference
LA English
AB The binding of selected peptides to lipid A of heterologous lipopolysaccharides was assessed and measured by the value of selectivity,
which expresses the ratio between the affinity const. value of Polymyxin B
and that of each synthetic peptide in competition anal. Both the ref. and
the synthetic peptides with a value of .gtoreq.0.75 Rc/h were able to inhibit competitively the lipid A-induced hemorrhagic necrosis in rabbits at doses as high as 75-125 .mu.g/mL of **LPS**.

L7 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2
AN 1993:145833 BIOSIS
DN PREV199395078633
TI Molecular mapping and detoxification of the lipid A binding site by synthetic peptides.
AU Rustici, Alessandro; Velucchi, Massimo; Faggioni, Raffaella; Sironi, Marina; Ghezzi, Pietro; Quataert, Sally; Green, Bruce; **Porro, Massimo**

(1)
CS (1) Biosynth Res. Lab., Rapolano Terme, Siena, Italy 53040
SO Science (Washington D C), (1993) Vol. 259, No. 5093, pp. 361-365.
ISSN: 0036-8075.
DT Article
LA English
AB Endotoxin (lipopolysaccharide (**LPS**)), the major antigen of the outer membrane of Gram-negative bacteria, consists of a variable-size carbohydrate chain that is covalently linked to N, 0-acylated beta-1, 6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of **LPS** residues in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxity **LPS** in vitro, and prevent **LPS** -induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy of prophylaxis and the treatment of **LPS**-mediated diseases.

=> s lps and peptid?

L8 6792 LPS AND PEPTID?

=> s l8 and stoichiometric

L9 93 L8 AND STOICHIOMETRIC

=> dup rem l9

PROCESSING COMPLETED FOR L9
L10 88 DUP REM L9 (5 DUPLICATES REMOVED)

=> s l10 and (gram negative or bacteria)

10 FILES SEARCHED...
L11 65 L10 AND (GRAM NEGATIVE OR BACTERIA)

=> s l11 and vaccin?

L12 14 L11 AND VACCIN?

=> d bib ab 1-14

L12 ANSWER 1 OF 14 USPATFULL
AN 2001:116819 USPATFULL
TI Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
IN Morgan, Antony R., late of Edmonton, Canada deceased
Morgan, Robert Charles, Toronto, Canada executor
Severini, Alberto, Edmonton, Canada
PA DNAB Diagnostics, Inc., Edmonton, Canada (non-U.S. corporation)
PI US 6265213 B1 20010724
AI US 2000-593323 20000613 (9)
RLI Division of Ser. No. US 1999-344300, filed on 24 Jun 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Wilder, Cynthia
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides plasmids that are useful in detecting and determining the DNA-binding activity of sequence-specific DNA-binding molecules. The invention further provides plasmids that are useful in detecting and determining the activity of RNA polymerases in initiating transcription. In particular, the invention relates to plasmids that contain unique restriction sites and cognate nucleotide recognition sequences for sequence-specific DNA-binding molecules. Also provided are methods for using the plasmids disclosed herein.

L12 ANSWER 2 OF 14 USPATFULL
AN 2000:131642 USPATFULL
TI Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having a endosome disruption agent
IN Boutin, Raymond H., Thornton, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 6127170 20001003
WO 9610038 19960404
AI US 1997-809397 19970321 (8)
WO 1995-US12502 19950928
19970321 PCT 371 date
19970321 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-314060, filed on 28 Sep 1994, now patented, Pat. No. US 5837533, issued on 17 Nov 1998
DT Utility
FS Granted
EXNAM Primary Examiner: Crouch, Deborah
LREP Howson and Howson
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4293
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided. The complex is comprised of A) said nucleic acid composition and B) a transfer moiety comprising 1) one or more cationic polyamines bound to said nucleic acid composition, 2) one or more endosome membrane disrupting components attached to at least one nitrogen of the polyamine and 3) one or more receptor specific binding components.

L12 ANSWER 3 OF 14 USPATFULL
AN 1998:143936 USPATFULL
TI Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
IN Boutin, Raymond H., Thornton, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 5837533 19981117
AI US 1994-314060 19940928 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Crouch, Deborah
LREP Howson and Howson
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3984
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided which comprises in any functional combination: A) said nucleic acid composition; and B) a transfer moiety comprising 1) one or more cationic polyamine components bound to said nucleic acid composition, each comprising from three to twelve nitrogen atoms; 2) one or more endosome membrane disruption promoting components attached to at least one nitrogen atom of at least one of said polyamine components, through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group, comprising a) at least one lipophilic long chain alkyl group, b) a fusogenic **peptide** comprising spike glycoproteins of enveloped animal viruses, or c) cholic acid or cholesteryl or derivatives; and optionally 3) one or more receptor specific binding components which are ligands for natural receptors of said target cell, attached through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group to either i) a further nitrogen atom of at least one of said polyamine components to which said one or more endosome membrane disruption promoting components is attached, or ii) a nitrogen atom of at least one further polyamine component which does not have attached thereto any endosome membrane disruption promoting component. Also provided are the transfer moiety alone, or in combination with the nucleic acid composition as a self-assembling combination, and the use of these compositions in methods for transfering nucleic acid compositions to cells or to cells of individuals, for immunizing individuals against a pathogen or disease, and for treating an individual with a disease.

L12 ANSWER 4 OF 14 USPATFULL
AN 97:66100 USPATFULL
TI **Peptides** for neutralizing the toxicity of Lipid A
IN Porro, Massimo, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5652211 19970729
AI US 1993-97830 19930726 (8)
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned , said Ser. No. US -49871 which is a continuation of Ser. No. US -658744
DT Utility
FS Granted
EXNAM Primary Examiner: Russell, Jeffrey E.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 39
ECL Exemplary Claim: 36,38
DRWN No Drawings
LN.CNT 683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with a **peptide** composition which includes a **peptide** having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which Is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or

different and are selected from the group consisting of Valine, Leucine,
Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with
a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L12 ANSWER 5 OF 14 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,
Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using **peptides** of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg;
B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products
with endotoxin.

L12 ANSWER 6 OF 14 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel **peptides** of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an
amino acid residue or a fatty acid residue; A is an amino acid residue

selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used inter alia for the prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L12 ANSWER 7 OF 14 USPATFULL
AN 93:107024 USPATFULL
TI Method of inhibiting the activity of leukocyte derived cytokines
IN Mandell, Gerald L., Earlysville, VA, United States
Sullivan, Gail W., Charlottesville, VA, United States
Novick, William J., Lebanon, NJ, United States
PA Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ, United States (U.S. corporation)
University of Virginia Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)
PI US 5272153 19931221
AI US 1992-908929 19920702 (7)
DCD 20080615
RLI Continuation of Ser. No. US 1991-700522, filed on 15 May 1991, now abandoned which is a continuation of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned And a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L12 ANSWER 8 OF 14 USPATFULL
AN 93:22715 USPATFULL
TI Method of inhibiting the activity of leukocyte derived cytokines
IN Mandell, Gerald L., Earlysville, VA, United States
Sullivan, Gail W., Charlottesville, VA, United States
Novick, William J., Lebanon, NJ, United States
PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States (U.S. corporation)
University of Virginia Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)
PI US 5196430 19930323
AI US 1991-762200 19910918 (7)
DCD 20071023
RLI Division of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented,

Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned which is a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned

DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branch alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L12 ANSWER 9 OF 14 USPATFULL
AN 93:22714 USPATFULL
TI Method of inhibiting the activity of leukocyte derived cytokines
IN Mandell, Gerald L., North Garden, VA, United States
Sullivan, Gail W., Charlottesville, VA, United States
Novick, William J., Lebanon, NJ, United States
PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States (U.S. corporation)
University of VA Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)
PI US 5196429 19930323
AI US 1991-738096 19910730 (7)
RLI Continuation of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned And a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986

DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1344
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and

R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L12 ANSWER 10 OF 14 USPATFULL
AN 89:14777 USPATFULL
TI Method for reducing bacterial endotoxin contamination in solutions of macromolecules
IN Karplus, Thomas E., Sydney, Australia
Ulevitch, Richard J., Del Mar, CA, United States
Wilson, Curtis B., San Diego, CA, United States
PA Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)
PI US 4808314 19890228
AI US 1987-98299 19870918 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Sever, Frank
LREP Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates a method of reducing a bacterial endotoxin contaminant in a biologically useful macromolecule. AN aqueous
medium containing an endotoxin-contaminated macromolecule is admixed with a dialyzable surfactant, and the admixture so formed is contacted with an endotoxin sorbant to form a solid-liquid phase admixture. The contacting is maintained until the endotoxin is bound to the sorbant. The surfactant is dialyzed out of the aqueous liquid phase at a time no earlier than the maintenance step. The liquid phase containing the macromolecule is separated and recovered.

L12 ANSWER 11 OF 14 USPATFULL
AN 83:11238 USPATFULL
TI Immunologically active dipeptidyl saccharides and methods of preparation
IN Durette, Philippe L., New Providence, NJ, United States
Shen, Tsung-Ying, Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4377570 19830322
AI US 1980-193777 19801003 (6)
RLI Division of Ser. No. US 1979-7108, filed on 29 Jan 1979, now patented, Pat. No. US 4256735
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Perrella, Donald J., Pfeiffer, Hesna J.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1,2
DRWN No Drawings
LN.CNT 1516
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;

R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

when R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

the stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.

L12 ANSWER 12 OF 14 USPATFULL
AN 83:1781 USPATFULL
TI Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
IN Shen, Tsung-Ying, Westfield, NJ, United States
Durette, Philippe L., New Providence, NJ, United States
Dorn, Jr., Conrad P., Plainfield, NJ, United States
Doherty, James B., New Milford, NJ, United States
Dean, Richard T., Fanwood, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4368190 19830111
AI US 1980-141227 19800417 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Perrella, Donald J., Speer, Raymond M., Pfeiffer, Hesna J.
CLMN Number of Claims: 34
ECL Exemplary Claim: 1,33,34
DRWN No Drawings
LN.CNT 1240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunologically active compounds of the formula: ##STR1## wherein: R.sub.1 is C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; or substituted phenyl;

R.sub.2 is hydrogen; C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; substituted phenyl; phenyl C.sub.1-4 alkyl; or substituted phenyl C.sub.1-4 alkyl;

R.sub.3 and R.sub.4 may be the same or different and are each independently hydrogen, provided that R.sub.3 and R.sub.4 may not both be hydrogen; or ##STR2## where X is --O--; --S--; or ##STR3## R.sub.10 is hydrogen; C.sub.1-30 alkyl; C.sub.2-30 alkenyl; C.sub.1-30 alkoxy; phenyl; C.sub.1-20 alkylsulfonyl; or cholesteryl;

R.sub.11, R.sub.12, R.sub.13, R.sub.14, and R.sub.15 may be the same or different and are each independently hydrogen; C.sub.1-20 alkyl; C.sub.1-20 alkylcarbonyloxy; amino; benzyl; C.sub.1-20 alkoxymethyl; C.sub.1-20 alkylamido; or ##STR4## r is 0 or 1; s is 0 or 1; and t is 0 to 20; provided that s may only be 0 when both r and t are greater than 0 or when r is 0 and R.sub.10 is amino; phenyl; substituted phenyl; 1-adamantyl; or heterocycle selected from the group consisting of 2- or 3-furyl, 2- or 3- thienyl, 2- or 3- pyrrolidinyl, 2-, 3- or 4- pyridyl, and 1-tetrazolyl, said heterocycle optionally substituted with C.sub.1-20 alkylcarbonyl; and where R.sub.3 or R.sub.4 is other than hydrogen, the other of R.sub.3 and R.sub.4 may additionally be C.sub.1-4 alkylcarbonyl;

R.sub.5 is hydrogen or C.sub.1-10 alkyl;

R.sub.6 is hydrogen or R.sub.6 and R.sub.7 taken together are --(CH.sub.2).sub.3 --;

R.sub.7 is hydrogen; C.sub.1-7 alkyl; hydroxymethyl; mercaptomethyl; benzyl; or substituted benzyl;

R.sub.8 and R.sub.9 may be the same or different and are each independently COOR, or CONR'R", where R is hydrogen or C.sub.1-7 alkyl, and R' and R" are hydrogen or C.sub.1-3 alkyl;

when R.sub.5 is C.sub.1-10 alkyl, the stereochemistry at asymmetric center I is D or L;

when R.sub.7 is other than hydrogen, the stereochemistry at asymmetric center II is L; and the stereochemistry at asymmetric center III is D; and acid addition and quaternary salts thereof.

L12 ANSWER 13 OF 14 USPATFULL
AN 81:14980 USPATFULL
TI Immunologically active dipeptidyl saccharides and methods of preparation
IN Durette, Philippe L., New Providence, NJ, United States
Shen, Tsung-Ying, Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4256735 19810317
AI US 1979-7108 19790129 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Phillips, Delbert R.; Assistant Examiner: Hazel, Blondel
LREP Perrella, Donald J., Levitt, Julian S.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1,14
DRWN No Drawings
LN.CNT 1559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;

R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

Provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

When R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

The stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.

L12 ANSWER 14 OF 14 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2000-128304 [12] WPIDS
DNC C2000-039402
TI New **vaccine** for prevention of **gram-negative** bacterial infections and endotoxin related disorders, comprises complex of **peptide** and **LPS**.
DC B04 B05 D16
IN PORRO, M
PA (BIOS-N) BIOSYNTH SRL
CYC 26
PI EP 976402 A2 20000202 (200012)* EN 43p
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
CA 2279316 A1 20000129 (200028) EN
ADT EP 976402 A2 EP 1999-202476 19990727; CA 2279316 A1 CA 1999-2279316 19990729
PRAI US 1998-124280 19980729
AB EP 976402 A UPAB: 20000308
NOVELTY - A **vaccine** for preventing **gram negative** infections and the effects of endotoxins is new and comprises a complex obtained by combining **LPS** free or in conjugate form with a sufficient amount of a **peptide** which is capable of producing a non-toxic, highly immunogenic complex.
DETAILED DESCRIPTION - A **vaccine** for preventing **gram negative** infections and the effects of endotoxins is new and comprises a complex obtained by combining **LPS** free or in conjugate form with a sufficient amount of a **peptide** which is capable of producing a non-toxic, highly immunogenic complex. The **peptide** is of the formula (a) - (c):
(a) (A)n;
(b) (AB)m; and/or
(c) (ABC)p.
A = a cationic amino acid e.g. Lysine or Arginine;
B = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;
C = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;
n = integer of 7-16;
m = integer of 4-20;
p = integer of 4-20.
An INDEPENDENT CLAIM is also included for a method for the

preparation of a **vaccine** for prevention of **gram-negative** infections and the effects of endotoxins.
ACTIVITY - Antibacterial.
No relevant activity data given.
MECHANISM OF ACTION - The excess **peptide** significantly stabilizes the **LPS peptide** complex from the likely antagonistic activity of natural **LPS**-receptor proteins present on specialized cells of the immune system.
USE - The **vaccine** is useful for the prevention of bacterial infections caused by **gram-negative bacteria** and for the prevention of biological effects of homologous endotoxins, especially for preventing sepsis and septic shock.
ADVANTAGE - The toxic characteristic of **LPS** may be removed without eliminating the antigenic and immunogenic properties of **LPS** by binding the **LPS** (via the lipid A moiety) to a **peptide**.
Dwg.0/0

=> d his

(FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA,
LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001
E PORRO MASSIMO/AU
E PORRO MASSIMO/AU
L1 40 S E3
L2 20 S L1 AND BACTERIA
L3 17 DUP REM L2 (3 DUPLICATES REMOVED)
L4 17 S L1 AND GRAM NEGATIVE
L5 8 S L4 AND LPS
L6 14 S L1 AND LPS
L7 12 DUP REM L6 (2 DUPLICATES REMOVED)
L8 6792 S LPS AND PEPTID?
L9 93 S L8 AND STOICHIOMETRIC
L10 88 DUP REM L9 (5 DUPLICATES REMOVED)
L11 65 S L10 AND (GRAM NEGATIVE OR BACTERIA)
L12 14 S L11 AND VACCIN?

=> s l10 and (meningtidis or salmonella or moraxella or e coli or influenzae or pseudomonas)

6 FILES SEARCHED...
L13 70 L10 AND (MENINGTIDIS OR SALMONELLA OR MORAXELLA OR E COLI OR INFLUENZAE OR PSEUDOMONAS)

=> s l13 and vaccin?

L14 12 L13 AND VACCIN?

=> d l13 bib ab 1-40

L13 ANSWER 1 OF 70 USPATFULL
AN 2001:121486 USPATFULL
TI Substituted aryl hydroxamic acids as metalloproteinase inhibitors
IN Xue, Chu-Biao, Hockessin, DE, United States
Decicco, Carl P., Newark, DE, United States
Wexler, Ruth R., Wilmington, DE, United States
PA DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)
PI US 6268379 B1 20010731

AI US 1999-311168 19990513 (9)
PRAI US 1998-85393 19980514 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davis, Zinna Northington
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1496
AB The present application describes novel substituted aryl hydroxamic acids of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-2 heteroatoms selected from N, 0, and S, which are useful as metalloprotease inhibitors.

L13 ANSWER 2 OF 70 USPATFULL
AN 2001:116819 USPATFULL
TI Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
IN Morgan, Antony R., late of Edmonton, Canada deceased
Morgan, Robert Charles, Toronto, Canada executor
Severini, Alberto, Edmonton, Canada
PA DNAB Diagnostics, Inc., Edmonton, Canada (non-U.S. corporation)
PI US 6265213 B1 20010724
AI US 2000-593323 20000613 (9)
RLI Division of Ser. No. US 1999-344300, filed on 24 Jun 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Wilder, Cynthia
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides plasmids that are useful in detecting and determining the DNA-binding activity of sequence-specific DNA-binding molecules. The invention further provides plasmids that are useful in detecting and determining the activity of RNA polymerases in initiating transcription. In particular, the invention relates to plasmids that contain unique restriction sites and cognate nucleotide recognition sequences for sequence-specific DNA-binding molecules. Also provided are

methods for using the plasmids disclosed herein.

L13 ANSWER 3 OF 70 USPATFULL
AN 2001:47850 USPATFULL
TI Methods for early detection of heart disease
IN Sabbadini, Roger A., Lakeside, CA, United States
PA Medlyte Diagnostics, Inc., Lakeside, CA, United States (U.S. corporation)
PI US 6210976 B1 20010403
AI US 1998-84069 19980522 (9)
PRAI US 1997-49274 19970610 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Chin, Christopher L.
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods, compositions, kits, and devices for

detecting cardiac ischemia, hypoxia, or other causes of heart failure in
a mammal by obtaining a test sample from a mammal, measuring a level of a non-polypeptidic cardiac marker in the test sample, and determining if
the level of the cardiac marker measured in said test sample correlates with cardiac ischemia or hypoxia or another form of heart failure.

L13 ANSWER 4 OF 70 USPATFULL
AN 2001:33283 USPATFULL
TI 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
IN DeNinno, Michael P., Gales Ferry, CT, United States
Magnus-Aryitey, George T., Ledyard, CT, United States
Ruggeri, Roger B., Waterford, CT, United States
Wester, Ronald T., Ledyard, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6197786 B1 20010306
AI US 1999-391152 19990907 (9)
PRAI US 1998-100860 19980917 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 5 OF 70 USPATFULL
AN 2001:1478 USPATFULL
TI Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
IN Ulevitch, Richard J., Del Mar, CA, United States
Tobias, Peter S., San Diego, CA, United States
Pugin, Jerome, Puplinge, Switzerland
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6168790 B1 20010102
AI US 1998-99957 19980619 (9)
RLI Continuation of Ser. No. US 1994-307931, filed on 16 Sep 1994, now abandoned Continuation-in-part of Ser. No. US 1992-990378, filed on 15 Dec 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Smith, Lynette R. F.; Assistant Examiner: Portner, Ginny Allen
LREP Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 1964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns a method of treating bacteremia, sepsis and other forms of toxemia caused by Gram-positive bacteria and mycobacteria comprising administering a therapeutically effective amount

of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

L13 ANSWER 6 OF 70 USPATFULL
AN 2000:157145 USPATFULL
TI Nuclear factors associated with transcriptional regulation
IN Baltimore, David, New York, NY, United States
Sen, Ranjan, Cambridge, MA, United States
Sharp, Phillip A., Newton, MA, United States
Singh, Harinder, Chicago, IL, United States
Staudt, Louis, Silver Springs, MD, United States
LeBowitz, Jonathan H., Zionsville, IN, United States
Baldwin, Jr., Albert S., Chapel Hill, NC, United States
Clerc, Roger G., Binningen, Switzerland
Corcoran, Lynn M., Port Melbourne, Australia
Baeuerle, Patrick A., Eichenau, Germany, Federal Republic of
Lenardo, Michael J., Potomac, MD, United States
Fan, Chen-Ming, San Francisco, MA, United States
Maniatis, Thomas P., Belmont, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
Whitehead Institute, Cambridge, MA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 6150090 20001121
AI US 1995-463397 19950605 (8)
RLI Division of Ser. No. US 1995-418266, filed on 6 Apr 1995, now patented, Pat. No. US 5804374 which is a continuation of Ser. No. US 1991-791898, filed on 13 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1986-946365, filed on 24 Dec 1986, now abandoned And a continuation-in-part of Ser. No. US 1989-318901, filed on 3 Mar 1989, now abandoned And a continuation-in-part of Ser. No. US 1988-162680, filed on 1 Mar 1988, now abandoned And a continuation-in-part of Ser. No. US 1989-341436, filed on 21 Apr 1989, now abandoned And a continuation-in-part of Ser. No. US 1986-817441, filed on 9 Jan 1986, now abandoned And a continuation-in-part of Ser. No. US 1988-155207, filed on 12 Feb 1988, now abandoned And a continuation-in-part of Ser. No. US 1988-280173, filed on 5 Dec 1988, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.
LREP Foley, Hoag & Eliot, LLP, Vincent, Matthew P., Clauss, Isabelle M.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 4899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB,
IkB and the gene encoding IkB and uses therefor.

L13 ANSWER 7 OF 70 USPATFULL
AN 2000:153723 USPATFULL
TI 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
IN DeNinno, Michael P., Gales Ferry, CT, United States
Mularski, Christian J., Chester, CT, United States
Ruggeri, Roger B., Waterford, CT, United States
Wester, Ronald T., Ledyard, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6147090 20001114
AI US 1999-391273 19990907 (9)
PRAI US 1998-100929 19980917 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 8 OF 70 USPATFULL
AN 2000:153722 USPATFULL
TI Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
IN DeNinno, Michael P., Gales Ferry, CT, United States
Ruggeri, Roger B., Waterford, CT, United States
Wester, Ronald T., Ledyard, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6147089 20001114
AI US 1999-390738 19990907 (9)
PRAI US 1998-100926 19980917 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 9 OF 70 USPATFULL
AN 2000:146389 USPATFULL
TI 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
IN DeNinno, Michael P., Gales Ferry, CT, United States
Magnus-Aryitey, George T., Ledyard, CT, United States
Ruggeri, Roger B., Waterford, CT, United States
Wester, Ronald T., Ledyard, CT, United States
PA Pfizer, New York, NY, United States (U.S. corporation)
PI US 6140343 20001031
AI US 1999-391313 19990907 (9)
PRAI US 1998-100927 19980917 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret

LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 10 OF 70 USPATFULL
AN 2000:146388 USPATFULL
TI Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
IN Goldstein, Steven W., Noank, CT, United States
Makowski, Michael R., Salem, CT, United States
Ruggeri, Roger B., Waterford, CT, United States
Wester, Ronald T., Ledyard, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6140342 20001031
AI US 1999-390731 19990907 (9)
PRAI US 1998-100729 19980917 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 11 OF 70 USPATFULL
AN 2000:131642 USPATFULL
TI Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having a endosome disruption agent
IN Boutin, Raymond H., Thornton, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 6127170 20001003
WO 9610038 19960404
AI US 1997-809397 19970321 (8)
WO 1995-US12502 19950928
19970321 PCT 371 date
19970321 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-314060, filed on 28 Sep 1994, now patented, Pat. No. US 5837533, issued on 17 Nov 1998
DT Utility
FS Granted
EXNAM Primary Examiner: Crouch, Deborah

LREP Howson and Howson
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4293
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided. The complex is comprised of A) said nucleic acid composition and B) a transfer moiety comprising 1) one or more cationic polyamines bound to said nucleic acid composition, 2) one or more endosome membrane disrupting components attached to at least one nitrogen of the polyamine and 3) one or more receptor specific binding components.

L13 ANSWER 12 OF 70 USPATFULL
AN 2000:125209 USPATFULL
TI Oligomeric compounds having nitrogen-containing linkages
IN Cook, Phillip Dan, Vista, CA, United States
Sanghvi, Yogesh S., San Marcos, CA, United States
Kung, Pei Pei, Carlsbad, CA, United States
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6121433 20000919
WO 9518623 19950713
AI US 1996-669300 19960808 (8)
WO 1995-US350 19950111
19960808 PCT 371 date
19960808 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-180124, filed on 11 Jan 1994, now patented, Pat. No. US 5783682 And a continuation-in-part of Ser. No. US 1993-39979, filed on 30 Mar 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-39846, filed on 30 Mar 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-40933, filed on 31 Mar 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-40903, filed on 31 Mar 1993, now patented, Pat. No. US 5386023 And a continuation-in-part of Ser. No. US 1993-40526, filed on 31 Mar 1993, now patented, Pat. No. US 5489677 which is a continuation-in-part of Ser. No. WO 1992-US4294, filed on 21 May 1992 And a continuation-in-part of Ser. No. US 1992-903160, filed on 24 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-703619, filed on 21 May 1991, now patented, Pat. No. US 5378825 which is a continuation-in-part of Ser. No. US 1990-566836, filed on 13 Aug 1990, now patented, Pat. No. US 5223618 And a continuation-in-part of Ser. No. US 1990-558663, filed on 27 Jul 1990, now patented, Pat. No. US 5138045
DT Utility
FS Granted
EXNAM Primary Examiner: Marschel, Ardin H.; Assistant Examiner: Riley, Jezia
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 3461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compounds and libraries of compounds based on nitrogen atoms that are joined together with spanner groups include "letters" i.e., functional groups, that are attached to the nitrogen atoms, to the spanner groups or to both the nitrogen atoms and the spanner groups to render the compounds and libraries of such compounds with diverse properties.

L13 ANSWER 13 OF 70 USPATFULL
AN 2000:117742 USPATFULL
TI 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
IN Robinson, Ralph P., Gales Ferry, CT, United States
Laird, Ellen R., Mystic, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6114361 20000905
AI US 1999-429937 19991029 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: McKane, Joseph; Assistant Examiner: Oswecki, Jane C.
LREP Richardson, Peter C., Ginsburg, Paul H., Jacobs, Seth
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 are as defined above, to pharmaceutical compositions and methods of treatment.

L13 ANSWER 14 OF 70 USPATFULL
AN 2000:113991 USPATFULL
TI Bicyclic hydroxamic acid derivatives
IN Robinson, Ralph Pelton, Gales Ferry, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6110964 20000829
WO 9952910 19991021
AI US 1999-402259 19990930 (9)
WO 1999-IB503 19990324
19990930 PCT 371 date
19990930 PCT 102(e) date
PRAI US 1998-81309 19980410 (60)
US 1997-55208 19970808 (60)
US 1997-55207 19970808 (60)
US 1997-62766 19971024 (60)
US 1997-68261 19971219 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Lambkin, Deborah C.
LREP Richardson, Peter C., Ginsburg, Paul H., Appleman, Polene W.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1## wherein Z and Q are as defined in the
specification, to pharmaceutical compositions containing them and to their medicinal use.

L13 ANSWER 15 OF 70 USPATFULL
AN 2000:106071 USPATFULL
TI Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
IN Larrick, James W., Woodside, CA, United States
Wright, Susan C., Saratoga, CA, United States
Hirata, Michimasa, Morioka, Japan
PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6103888 20000815
AI US 1999-322911 19990601 (9)
RLI Continuation of Ser. No. US 1996-691280, filed on 1 Aug 1996 which is a continuation-in-part of Ser. No. US 313681

DT Utility
FS Granted
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian granulocytes, particularly including a reactive nitrogen inhibiting **peptide** (RNIP) fragment found at the carboxy-terminus of CAP18. Polypeptides are capable of binding to **LPS** and inhibiting **LPS**-mediated activation of macrophage, as well as interfering with the clotting cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in a suitable pharmaceutical carrier are also provided.

L13 ANSWER 16 OF 70 USPATFULL
AN 2000:84288 USPATFULL
TI Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IN Liverton, Nigel J., Harleysville, PA, United States
Claiborne, Christopher F., Lansdale, PA, United States
Claremon, David A., Maple Glen, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6083949 20000704
AI US 1998-13527 19980126 (9)
RLI Continuation-in-part of Ser. No. US 1996-717955, filed on 23 Sep 1996, now patented, Pat. No. US 5717100
DT Utility
FS Granted
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
LREP Korsen, Elliott, Daniel, Mark R.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2974
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds represented by formula I: ##STR1## are disclosed. AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom.

A pharmaceutical composition is also included.

Methods of treating cancer and cytokine mediated diseases are also included.

L13 ANSWER 17 OF 70 USPATFULL
AN 2000:61580 USPATFULL
TI Method for using lipoprotein associated coagulation inhibitor to treat sepsis
IN Creasey, Abla A., Piedmont, CA, United States
Broze, George J., Ladue, MO, United States
PA Washington University & Chiron Corp., United States (U.S. corporation)
PI US 6063764 20000516
AI US 1995-472761 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-224118, filed on 29 Mar 1994, now abandoned which is a continuation of Ser. No. US 1993-20427, filed on 22 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-897135, filed on 11 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1994-253427, filed on 2 Jun 1994, now abandoned which is a continuation of Ser. No. US 1993-4505, filed on 13 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-891947, filed on 1 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1994-270455, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1992-891947, filed on 1 Jun 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia; Assistant Examiner: Delacroix-Muirheid, C.
LREP Banner & Witcoff, Ltd.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to pateints. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.

L13 ANSWER 18 OF 70 USPATFULL
AN 2000:41164 USPATFULL
TI Antisense oligodeoxynucleotides regulating expression of TNF-.alpha.
IN Power, Christopher, Calgary, Canada
Mayne, Michael B., Winnipeg, Canada
PA University Technologies International, Inc., Canada (non-U.S. corporation)
PI US 6046319 20000404
AI US 1998-176862 19981022 (9)
PRAI US 1997-62718 19971022 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Epps, Janet L.
LREP Kohn & Associates
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1447
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A synthetic nuclease resistant antisense oligodeoxynucleotide capable of selectively modulating expression of human tumor necrosis factor-alpha by targeting exon sequences flanking donor splice sites, thereby regulating expression of TNF-.alpha. in a patient in need of such therapy is provided. In an embodiment either AS-ODN having the sequence set forth in SEQ ID No:4 or SEQ ID No:6 or a combination thereof can be used. The AS-ODN is administered either as the active ingredient in a pharmaceutical composition or by utilizing gene therapy techniques as an expression vector.

L13 ANSWER 19 OF 70 USPATFULL
AN 2000:40640 USPATFULL

TI Methods and compositions for ameliorating the symptoms of sepsis
IN Ulevitch, Richard, Del Mar, CA, United States
Tobias, Peter, Encinitas, CA, United States
Wright, Samuel D., New York, NY, United States
Mathison, John C., San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6045795 20000404
AI US 1997-906400 19970805 (8)
RLI Continuation of Ser. No. US 1994-328554, filed on 25 Oct 1994, now patented, Pat. No. US 5730980 which is a continuation of Ser. No. US 1992-990378, filed on 15 Dec 1992, now abandoned which is a continuation of Ser. No. US 1989-387817, filed on 1 Aug 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Budens, Robert D.
LREP Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

L13 ANSWER 20 OF 70 USPATFULL
AN 2000:4818 USPATFULL
TI 2-(arylalkenyl) azacycloalkane derivatives as ligands for sigma receptors
IN Calvet, Alain Pierre, L'Hay-les-Roses, France
Jacobelli, Henry, Paray-Vieille-Poste, France
Junien, Jean-Louis, Sevres, France
Riviere, Pierre, Paris, France
Roman, Fran.cedilla.ois-Joseph, Vitry-sur-Seine, France
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 6013656 20000111
AI US 1998-145918 19980902 (9)
RLI Division of Ser. No. US 1996-652567, filed on 7 Jun 1996, now patented, Pat. No. US 5849760 which is a continuation of Ser. No. WO 1994-FR1439, filed on 9 Dec 1994
PRAI FR 1993-14814 19931209
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Ashbrook, Charles W.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New 2-(arylalkenyl)azacycloalkane derivatives which are ligands for sigma receptors, of the formula (I) ##STR1## in which: Ar is aryl or heteroaryl, optionally mono- to trisubstituted,

m has the value 1 or 2,

n has the value 1 to 3,

R is phenyl, or cycloalkyl containing 3 to 7 carbon atoms,

their isomers and their addition salts.

Medicinal drugs which are antipsychotic agents and are useful in gastroenterology.

L13 ANSWER 21 OF 70 USPATFULL
AN 1999:132526 USPATFULL
TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
IN Goldberg, Alfred L., Brookline, MA, United States
PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5972636 19991026
AI US 1997-982295 19971202 (8)
RLI Division of Ser. No. US 1996-730310, filed on 11 Oct 1996, now patented, Pat. No. US 5786329 which is a division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented, Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L13 ANSWER 22 OF 70 USPATFULL
AN 1999:113766 USPATFULL
TI Triaryl substituted imidazoles, compositions containing such compounds and methods of use
IN Chang, Linda L., Wayne, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5955480 19990921
AI US 1997-972021 19971117 (8)
PRAI US 1996-31467 19961120 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Fan, Jane
LREP Yang, Mollie M., Rose, David L.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2,4-Diaryl-5-pyridylimidazoles are glucagon antagonists and inhibitors of the biosynthesis and/or action of TNF-.alpha. and IL-1. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose. The instant imidazoles are also inhibitors of TNF-.alpha. and IL-1. Compounds of the present invention may be used for

glucagon-mediated as well as cytokine mediated diseases. Cytokine mediated diseases refers to diseases or conditions in which excessive or unregulated production of one or more cytokines occurs. Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are cytokines produced by a variety of cells, which are involved in immunoregulation and other physiological conditions, such as inflammation.

L13 ANSWER 23 OF 70 USPATFULL
AN 1999:113664 USPATFULL
TI Methods and kits for the amplification of thin film based assays
IN Maul, Diana M., Thornton, CO, United States
Bogart, Gregory R., Fort Collins, CO, United States
PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)
PI US 5955377 19990921
AI US 1995-403565 19950417 (8)
RLI Continuation of Ser. No. US 1993-75693, filed on 10 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-923090, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-653052, filed on 11 Feb 1991
PRAI EP 1991-308968 19911001
DT Utility
FS Granted
EXNAM Primary Examiner: Chin, Christopher L.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 62 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 5421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for detecting an analyte of interest, comprising the steps of providing a detection device comprising a light reflective or transmissive substrate supporting one or more layers comprising an adhering attachment layer to which is affixed a receptive material which specifically interacts with the analyte of interest; reacting the device with a sample potentially comprising the analyte under conditions in which the analyte binds to the receptive material; and reacting bound analyte with a reagent which creates a mass change on the surface of the device.

L13 ANSWER 24 OF 70 USPATFULL
AN 1999:89171 USPATFULL
TI Matrix metalloprotease inhibitors
IN Bender, Steven Lee, Oceanside, CA, United States
Broka, Chris Allen, Foster City, CA, United States
Campbell, Jeffrey Allen, Fremont, CA, United States
Castelhano, Arlindo Lucas, New York, NY, United States
Fisher, Lawrence Emerson, Mountain View, CA, United States
Hendricks, Robert Than, Palo Alto, CA, United States
Sarma, Keshab, Sunnyvale, CA, United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
Agouron Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5932595 19990803
AI US 1996-769049 19961218 (8)
PRAI US 1996-22439 19960807 (60)
US 1995-8939 19951220 (60)
US 1996-32096 19961204 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Covington, Raymond
LREP Peries, Rohan

CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I: ##STR1## that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.

L13 ANSWER 25 OF 70 USPATFULL
AN 1999:89112 USPATFULL
TI Compositions for neutralization of lipopolysaccharides
IN Wright, Samuel D., Larchmont, NY, United States
Wurfel, Mark M., New York, NY, United States
Hailman, Peter Eric, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5932536 19990803
AI US 1994-337611 19941110 (8)
RLI Continuation-in-part of Ser. No. US 1994-259957, filed on 14 Jun 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Mohamed, Abdel A.
LREP Klauber & Jackson
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 2132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for neutralizing lipopolysaccharide, and treatment of gram-negative sepsis based therein. Accordingly, the invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or **LPS** binding protein. The lipid exchange protein is characterized by being capable of facilitating an exchange protein of lipopolysaccharide into the particles. In a specific embodiment, exemplified herein, the lipid particles are high density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol or a lipid bilayer binding derivative thereof. In a specific example, the phospholipid is phosphatidylcholine (PC). In a specific example, the ratio of phosphatidylcholine:cholesterol:apolipoprotein A-I is approximately 80:4:1. The levels of **LPS** exchange protein activity in a sample from a patient provides a diagnostic, monitoring, or prognostic indicator for a subject with endotoxemia, gram-negative sepsis, or septic shock.

L13 ANSWER 26 OF 70 USPATFULL
AN 1999:84975 USPATFULL
TI Compositions for neutralization of lipopolysaccharides
IN Wright, Samuel D., Westfield, NJ, United States
Wurfel, Mark M., New York, NY, United States
Hailman, Peter Eric, New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5928624 19990727
WO 9534289 19951221
AI US 1996-750697 19961216 (8)
WO 1995-US7903 19950607
19961216 PCT 371 date

RLI Continuation-in-part of Ser. No. US 1994-337611, filed on 10 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-259957, filed on 14 Jun 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Klauber & Jackson
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 2562
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for neutralizing lipopolysaccharide, and treatment of gram-negative sepsis based thereon. Accordingly, the invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or **LPS** binding protein. The lipid exchange protein is characterized by being capable of faciliting an exchange of lipopolysaccharide into the particles. In a specific embodiment, exemplified herein, the lipid particles are high density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol or a lipid bilayer binding derivative thereof. In a specific example, the phospholipid is phosphatidylcholine (PC). In a specific example, the ratio of phosphatidylcholine: cholesterol: apolipoprotein A-I is approximately 80:4:1. The level of **LPS** exchange protein activity in a sample from a patient provides a diagnostic, monitoring, or prognostic indicator for a subject with endotoxemia, gram-negative sepsis, or septic shock.

L13 ANSWER 27 OF 70 USPATFULL
AN 1999:18941 USPATFULL
TI Methods for detection of gram negative bacteria
IN Bogart, Gregory R., Berthoud, CO, United States
Moddel, Garret R., Boulder, CO, United States
Maul, Diana M., Thornton, CO, United States
Etter, Jeffrey B., Boulder, CO, United States
Crosby, Mark, Niwot, CO, United States
PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)
PI US 5869272 19990209
AI US 1995-455652 19950531 (8)
RLI Division of Ser. No. US 1993-75952, filed on 10 Jun 1993, now patented, Pat. No. US 5541057 which is a continuation-in-part of Ser. No. US 1992-924343, filed on 31 Jul 1992, now abandoned Ser. No. Ser. No. US 1992-873097, filed on 24 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408291, filed on 18 Sep 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Chin, Christopher L.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 62 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 5224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for the determination of chlamydial or gram negative bacterial antigen comprising contacting a sample potentially containing extracted antigen with an optically active surface comprising an attachment layer, and a layer of non-specific protein.

L13 ANSWER 28 OF 70 USPATFULL
AN 1998:157362 USPATFULL
TI 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors
IN Calvet, Alain Pierre, L'Hay-les-Roses, France
Jacobelli, Henry, Paray-Vieille-Poste, France
Junien, Jean-Louis, Sevres, France
Riviere, Pierre, Paris, France
Roman, Fran.cedilla.ois-Joseph, Vitry-sur-Seine, France
PA Institut de Recherche Jouveinal, Fresnes, France (non-U.S. corporation)
PI US 5849760 19981215
WO 9515948 19950615
AI US 1996-652567 19960607 (8)
WO 1993-FR9401439 19931209
19960110 PCT 371 date
19960110 PCT 102(e) date
PRAI FR 1993-14814 19931209
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Crissey, Todd M.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New 2-(arylalkenyl)azacycloalkane derivatives which are ligands for sigma receptors, of the formula (I) ##STR1## in which: Ar is aryl or heteroaryl, optionally mono- to trisubstituted,

m has the value 1 or 2,

n has the value 1 to 3,

R is phenyl, or cycloalkyl containing 3 to 7 carbon atoms,

their isomers and their addition salts. Medicinal drugs which are antipsychotic agents and are useful in gastroenterology.

L13 ANSWER 29 OF 70 USPATFULL
AN 1998:143936 USPATFULL
TI Complexes comprising a nucleic acid bound to a cationic polyamine having
an endosome disruption agent
IN Boutin, Raymond H., Thornton, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 5837533 19981117
AI US 1994-314060 19940928 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Crouch, Deborah
LREP Howson and Howson
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3984
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided which comprises in any functional combination: A) said nucleic acid composition; and B) a transfer moiety comprising 1) one or more cationic polyamine components bound to said nucleic acid composition, each comprising from three to twelve nitrogen atoms; 2) one or more endosome membrane disruption promoting components attached to at least one nitrogen atom of at least

one of said polyamine components, through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group, comprising a) at least one lipophilic long chain alkyl group, b) a fusogenic **peptide** comprising spike glycoproteins of enveloped animal viruses, or c) cholic acid or cholesteryl or derivatives; and optionally

3) one or more receptor specific binding components which are ligands for natural receptors of said target cell, attached through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group to either i) a further nitrogen atom of at least one of said polyamine components to which said one or more endosome membrane disruption promoting components is attached, or ii) a nitrogen atom of at least one further polyamine component which does not have attached thereto any endosome membrane disruption promoting component. Also provided are the transfer moiety alone, or in combination with the nucleic acid composition as a self-assembling combination, and the use of these compositions in methods for transfering nucleic acid compositions to cells or to cells of individuals, for immunizing individuals against a pathogen or disease, and for treating an individual with a disease.

L13 ANSWER 30 OF 70 USPATFULL
AN 1998:108431 USPATFULL
TI Aromatic hydroxamic acid compounds, their production and use
IN Kato, Kaneyoshi, Kawanishi, Japan
Miki, Shokyo, Ibaraki, Japan
Naruo, Ken-ichi, Sanda, Japan
Takahashi, Hideki, Ikeda, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5804601 19980908
AI US 1996-629623 19960409 (8)
PRAI JP 1995-84342 19950410
JP 1995-215932 19950824
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Fitzpatrick, Cella, Harper & Scinto
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a compound of the formula: ##STR1## wherein Ar represents an optionally substituted aromatic group; Q represents a divalent aliphatic hydrocarbon group; R.sub.1 represents hydrogen, cyano, an optionally substituted hydrocarbon group, a group of the formula: ##STR2## wherein R.sup.3 and R.sub.4 independently represent hydrogen, acyl or an optionally substituted hydrocarbon group, or R.sup.3 and R.sup.4 jointly form a ring, or acyl; R.sup.2 represents acyl; ..... represents a single bond or a double bond; m represents 1 or 2 or a salt, a process of producing thereof and an anti-neurodegenerative composition.

L13 ANSWER 31 OF 70 USPATFULL
AN 1998:108212 USPATFULL
TI Nuclear factors associates with transcriptional regulation
IN Baltimore, David, New York, NY, United States
Sen, Ranjan, Cambridge, MA, United States
Sharp, Phillip A., Newton, MA, United States
Singh, Harinder, Chicago, IL, United States
Staudt, Louis, Silver Springs, MD, United States
LeBowitz, Jonathan H., Zionsville, IN, United States
Baldwin, Jr., Albert S., Chapel Hill, NC, United States

Clerc, Roger G., Binningen, Switzerland
Corcoran, Lynn M., Victoria, Australia
Baeuerle, Patrick A., Eichenau, Germany, Federal Republic of
Lenardo, Michael J., Potomac, MD, United States
Fan, Chen-Ming, San Francisco, MA, United States
Maniatis, Thomas P., Belmont, MA, United States
PA Massachusetts Insti. Technology, Cambridge, MA, United States (U.S. corporation)
Whitehead Insti., Cambridge, MA, United States (U.S. corporation)
Pres. and Fellow of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5804374 19980908
AI US 1995-418266 19950406 (8)
RLI Continuation of Ser. No. US 1991-791898, filed on 13 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1986-946365, filed on 24 Dec 1986, now abandoned And Ser. No. US 1989-318901, filed on 3 Mar 1989, now abandoned And Ser. No. US 1988-162680, filed on 1 Mar
1988, now abandoned And Ser. No. US 1989-341436, filed on 21 Apr 1989, now abandoned And Ser. No. US 1986-817441, filed on 9 Jan 1986, now abandoned And Ser. No. US 1988-155207, filed on 12 Feb 1988, now abandoned And Ser. No. US 1980-280173, filed on 5 Dec 1980, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Degen, Nancy
LREP Hamilton, Brook, Smith & Reynolds, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 4692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB,
IkB and the gene encoding IkB and uses therefor.

L13 ANSWER 32 OF 70 USPATFULL
AN 1998:108028 USPATFULL
TI Treatment of lipopolysaccharide- or CD14-mediated conditions using soluble CD14
IN Goyert, Sanna M., 10 Waterside Plz., Apt. 36F, New York, NY, United States 10010
PA Goyert, Sanna M., New York, NY, United States (U.S. individual)
PI US 5804189 19980908
AI US 1994-254095 19940606 (8)
RLI Continuation-in-part of Ser. No. US 1992-863913, filed on 6 Apr 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Spector, Lorraine M.
LREP Cooper, Iver P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for the treatment of symptoms of sepsis and other conditions that are mediated by the action of CD14 myelomonocytic antigen ("CD14"). The embodiments herein include treatments for symptoms

of sepsis that are triggered by lipopolysaccharide ("**LPS**"). A genetically engineered recombinant soluble CD14 ("rsCD14") and fragments thereof are also provided. Both rsCD14 and a fragment thereof have been isolated and purified. The rsCD14 or fragments thereof can be administered to mammals to prevent or treat symptoms that are associated with sepsis.

L13 ANSWER 33 OF 70 USPATFULL
AN 1998:88814 USPATFULL
TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
IN Goldberg, Alfred L., Brookline, MA, United States
PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5786329 19980728
AI US 1996-730310 19961011 (8)
RLI Division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented, Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L13 ANSWER 34 OF 70 USPATFULL
AN 1998:51440 USPATFULL
TI Method of rapid analyte detection
IN Olstein, Alan D., Mendota Heights, MN, United States
Albert, Richard, Eden Prairie, MN, United States
PA MicroQuest Diagnostics, Inc., Eden Prairie, MN, United States (U.S. corporation)
PI US 5750357 19980512
AI US 1995-380643 19950130 (8)
RLI Continuation-in-part of Ser. No. US 1994-245374, filed on 18 May 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Scheiner, Toni R.
LREP Mueting, Raasch & Gebhardt, P.A.
CLMN Number of Claims: 32
ECL Exemplary Claim: 11,14
DRWN No Drawings
LN.CNT 872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A detectable synthetic copolymer useful to detect the presence of a microorganism in a test sample is provided. The copolymer comprises repeating monomeric units, which incorporate a population of first monomeric units each comprising a binding agent which binds to a

microorganism having multiple binding sites for said binding agent and which further incorporates a population of a second monomeric units each
comprising a detectable label or a binding site for a detectable label.

L13 ANSWER 35 OF 70 USPATFULL
AN 1998:39493 USPATFULL
TI Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
IN Roy, Soumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5739101 19980414
AI US 1995-440814 19950515 (8)
RLI Division of Ser. No. US 1994-246978, filed on 20 May 1994, now patented,
Pat. No. US 5589363 which is a division of Ser. No. US 1991-714819, filed on 13 Jun 1991, now patented, Pat. No. US 5346991
DT Utility
FS Granted
EXNAM Primary Examiner: Jacobson, Dian C.
LREP Kubinec, Jeffrey S.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 2482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful
in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.

L13 ANSWER 36 OF 70 USPATFULL
AN 1998:30695 USPATFULL
TI Methods and compositions for ameliorating the symptoms of sepsis
IN Ulevitch, Richard, Del Mar, CA, United States
Tobias, Peter, Encinitas, CA, United States
Wright, Samuel D., New York, NY, United States
Mathison, John C., San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5730980 19980324
AI US 1994-328554 19941025 (8)
RLI Continuation of Ser. No. US 1992-990378, filed on 15 Dec 1992, now abandoned which is a continuation of Ser. No. US 1989-387817, filed on 1
Aug 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Sidberry, Hazel F.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns a method of treating CD14-mediated host inflammatory response to **LPS** often associated with sepsis comprising administering a therapeutically effective amount of anti-CD14
antibody molecules. A therapeutic composition comprising anti-CD14

antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

L13 ANSWER 37 OF 70 USPATFULL
AN 1998:14942 USPATFULL
TI Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IN Selnick, Harold G., Ambler, PA, United States
Claremon, David A., Maple Glen, PA, United States
Liverton, Nigel J., Harleysville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5717100 19980210
AI US 1996-717955 19960923 (8)
PRAI US 1995-5063 19951006 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.
LREP Billups, Richard C., Daniel, Mark R.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3169
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds represented by formula I: ##STR1## are disclosed. AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 6 membered non-aromatic heterocycle containing only one N atom.

A pharmaceutical composition is also included.

Methods of treating cancer and cytokine mediated diseases are also included.

L13 ANSWER 38 OF 70 USPATFULL
AN 97:120632 USPATFULL
TI Methods of increasing thrombomodulin expression
IN Calnek, David S., Indianapolis, IN, United States
Grinnell, Brian W., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5700815 19971223
AI US 1995-517517 19950821 (8)
RLI Continuation of Ser. No. US 1993-170944, filed on 21 Dec 1993, now patented, Pat. No. US 5476862
DT Utility
FS Granted
EXNAM Primary Examiner: Fay, Zohreh
LREP Sales, James J.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of increasing thrombomodulin expression comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl;

R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

wherein

R.sup.1 and R.sup.3 are independently hydrogen, ##STR3## wherein Ar is optionally substituted phenyl;

R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.

Also encompassed by the invention is a method of inhibiting a thrombotic disorder or event which includes administering to a human in need thereof an effective amount of a compound of formula 1.

Also encompassed by the invention is a method of increasing Protein C activation rate which includes the administration of a compound of formula 1.

L13 ANSWER 39 OF 70 USPATFULL
AN 97:51921 USPATFULL
TI Methods for optimizing of an optical assay device
IN Bogart, Gregory R., Fort Collins, CO, United States
Etter, Jeffrey B., Boulder, CO, United States
PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)
PI US 5639671 19970617
AI US 1995-412600 19950328 (8)
RLI Continuation of Ser. No. US 1993-76319, filed on 10 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-923048, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-873097, filed on 24 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408291, filed on 18 Sep 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Chin, Christopher L.
LREP Lyon & Lyon
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 62 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 5193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for optimizing an optical assay device for an analyte, including the steps of: providing a substrate having a chosen thickness of an optically active layer thereon; providing an attachment layer of a chosen thickness on the optical coating; providing a receptive layer of a chosen thickness for the analyte, wherein at least one of the thicknesses of the optically active layer, attachment layer and receptive layer is varied to provide a plurality of thicknesses of that layer; contacting analyte with the receptive layer under conditions in which an increase in mass on the receptive layer results; and determining the optical thickness of the layer.

L13 ANSWER 40 OF 70 USPATFULL
AN 97:42799 USPATFULL
TI Method and instrument for detection of change of thickness or refractive index for a thin film substrate
IN Sandstrom, Torbjorn, Molnlycke, Sweden
Stiblert, Lars, G oteborg, Sweden
Maul, Diana M., Thornton, CO, United States
PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)
PI US 5631171 19970520
AI US 1995-455493 19950531 (8)
RLI Continuation of Ser. No. US 1993-75128, filed on 10 Jun 1993, now patented, Pat. No. US 5494829 which is a continuation-in-part of Ser. No. US 1992-923268, filed on 31 Jul 1992, now abandoned

DT Utility
FS Granted
EXNAM Primary Examiner: Chin, Christopher L.
LREP Lyon & Lyon
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 62 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 5160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An instrument configured and arranged to detect a change in thickness or
refractive index of a thin film substrate. A method for optimizing the instrument and a method for detecting a change in thickness or refractive index of a thin film substrate.

=> d bib ab 1-80

L14 ANSWER 1 OF 12 USPATFULL
AN 2001:116819 USPATFULL
TI Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
IN Morgan, Antony R., late of Edmonton, Canada deceased
Morgan, Robert Charles, Toronto, Canada executor
Severini, Alberto, Edmonton, Canada
PA DNAB Diagnostics, Inc., Edmonton, Canada (non-U.S. corporation)
PI US 6265213 B1 20010724
AI US 2000-593323 20000613 (9)
RLI Division of Ser. No. US 1999-344300, filed on 24 Jun 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Wilder, Cynthia
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides plasmids that are useful in detecting and determining the DNA-binding activity of sequence-specific DNA-binding molecules. The invention further provides plasmids that are useful in detecting and determining the activity of RNA polymerases in initiating transcription. In particular, the invention relates to plasmids that contain unique restriction sites and cognate nucleotide recognition sequences for sequence-specific DNA-binding molecules. Also provided are
methods for using the plasmids disclosed herein.

L14 ANSWER 2 OF 12 USPATFULL
AN 2000:131642 USPATFULL
TI Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having a endosome disruption agent
IN Boutin, Raymond H., Thornton, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 6127170 20001003
WO 9610038 19960404
AI US 1997-809397 19970321 (8)
WO 1995-US12502 19950928
19970321 PCT 371 date
19970321 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-314060, filed on 28 Sep 1994,

now patented, Pat. No. US 5837533, issued on 17 Nov 1998
DT Utility
FS Granted
EXNAM Primary Examiner: Crouch, Deborah
LREP Howson and Howson
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4293
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided. The complex is comprised of A) said nucleic acid composition and B) a transfer moiety comprising 1) one or more cationic polyamines bound to said nucleic acid composition, 2) one or more endosome membrane disrupting components attached to at least one nitrogen of the polyamine and 3) one or more receptor specific binding components.

L14 ANSWER 3 OF 12 USPATFULL
AN 1998:143936 USPATFULL
TI Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
IN Boutin, Raymond H., Thornton, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 5837533 19981117
AI US 1994-314060 19940928 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Crouch, Deborah
LREP Howson and Howson
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3984
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided which comprises in any functional combination: A) said nucleic acid composition; and B) a transfer moiety comprising 1) one or more cationic polyamine components bound to said nucleic acid composition, each comprising from three to twelve nitrogen atoms; 2) one or more endosome membrane disruption promoting components attached to at least one nitrogen atom of at least one of said polyamine components, through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group, comprising a) at least one lipophilic long chain alkyl group, b) a fusogenic **peptide** comprising spike glycoproteins of enveloped animal viruses, or c) cholic acid or cholesteryl or derivatives; and optionally 3) one or more receptor specific binding components which are ligands for natural receptors of said target cell, attached through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group to either i) a further nitrogen atom of at least one of said polyamine components to which said one or more endosome membrane disruption promoting components is attached, or ii) a nitrogen atom of at least one further polyamine component which does not have attached thereto any endosome membrane disruption promoting component. Also provided are the transfer moiety alone, or in combination with the nucleic acid composition as a self-assembling combination, and the use of these compositions in methods for transfering nucleic acid compositions to

cells or to cells of individuals, for immunizing individuals against a pathogen or disease, and for treating an individual with a disease.

L14 ANSWER 4 OF 12 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,
Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using **peptides** of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg;
B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products
with endotoxin.

L14 ANSWER 5 OF 12 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel **peptides** of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an
amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used inter alia for the

prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L14 ANSWER 6 OF 12 USPATFULL
AN 93:107024 USPATFULL
TI Method of inhibiting the activity of leukocyte derived cytokines
IN Mandell, Gerald L., Earlysville, VA, United States
Sullivan, Gail W., Charlottesville, VA, United States
Novick, William J., Lebanon, NJ, United States
PA Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ, United States (U.S. corporation)
University of Virginia Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)
PI US 5272153 19931221
AI US 1992-908929 19920702 (7)
DCD 20080615
RLI Continuation of Ser. No. US 1991-700522, filed on 15 May 1991, now abandoned which is a continuation of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned And a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L14 ANSWER 7 OF 12 USPATFULL
AN 93:22715 USPATFULL
TI Method of inhibiting the activity of leukocyte derived cytokines
IN Mandell, Gerald L., Earlysville, VA, United States
Sullivan, Gail W., Charlottesville, VA, United States
Novick, William J., Lebanon, NJ, United States
PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States (U.S. corporation)
University of Virginia Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)
PI US 5196430 19930323
AI US 1991-762200 19910918 (7)
DCD 20071023
RLI Division of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now

abandoned which is a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branch alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L14 ANSWER 8 OF 12 USPATFULL
AN 93:22714 USPATFULL
TI Method of inhibiting the activity of leukocyte derived cytokines
IN Mandell, Gerald L., North Garden, VA, United States
Sullivan, Gail W., Charlottesville, VA, United States
Novick, William J., Lebanon, NJ, United States
PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States (U.S. corporation)
University of VA Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)
PI US 5196429 19930323
AI US 1991-738096 19910730 (7)
RLI Continuation of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned And a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1344
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be

substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L14 ANSWER 9 OF 12 USPATFULL
AN 89:14777 USPATFULL
TI Method for reducing bacterial endotoxin contamination in solutions of macromolecules
IN Karplus, Thomas E., Sydney, Australia
Ulevitch, Richard J., Del Mar, CA, United States
Wilson, Curtis B., San Diego, CA, United States
PA Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)
PI US 4808314 19890228
AI US 1987-98299 19870918 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Sever, Frank
LREP Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates a method of reducing a bacterial endotoxin contaminant in a biologically useful macromolecule. AN aqueous
medium containing an endotoxin-contaminated macromolecule is admixed with a dialyzable surfactant, and the admixture so formed is contacted with an endotoxin sorbant to form a solid-liquid phase admixture. The contacting is maintained until the endotoxin is bound to the sorbant. The surfactant is dialyzed out of the aqueous liquid phase at a time no earlier than the maintenance step. The liquid phase containing the macromolecule is separated and recovered.

L14 ANSWER 10 OF 12 USPATFULL
AN 83:11238 USPATFULL
TI Immunologically active dipeptidyl saccharides and methods of preparation
IN Durette, Philippe L., New Providence, NJ, United States
Shen, Tsung-Ying, Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4377570 19830322
AI US 1980-193777 19801003 (6)
RLI Division of Ser. No. US 1979-7108, filed on 29 Jan 1979, now patented, Pat. No. US 4256735
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Perrella, Donald J., Pfeiffer, Hesna J.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1,2
DRWN No Drawings
LN.CNT 1516
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;

R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

when R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

the stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.

L14 ANSWER 11 OF 12 USPATFULL
AN 83:1781 USPATFULL
TI Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
IN Shen, Tsung-Ying, Westfield, NJ, United States
Durette, Philippe L., New Providence, NJ, United States
Dorn, Jr., Conrad P., Plainfield, NJ, United States
Doherty, James B., New Milford, NJ, United States
Dean, Richard T., Fanwood, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4368190 19830111
AI US 1980-141227 19800417 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Perrella, Donald J., Speer, Raymond M., Pfeiffer, Hesna J.
CLMN Number of Claims: 34
ECL Exemplary Claim: 1,33,34
DRWN No Drawings
LN.CNT 1240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunologically active compounds of the formula: ##STR1## wherein: R.sub.1 is C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; or substituted phenyl;

R.sub.2 is hydrogen; C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; substituted phenyl; phenyl C.sub.1-4 alkyl; or substituted phenyl C.sub.1-4 alkyl;

R.sub.3 and R.sub.4 may be the same or different and are each independently hydrogen, provided that R.sub.3 and R.sub.4 may not both be hydrogen; or ##STR2## where X is --O--; --S--; or ##STR3## R.sub.10 is hydrogen; C.sub.1-30 alkyl; C.sub.2-30 alkenyl; C.sub.1-30 alkoxy; phenyl; C.sub.1-20 alkylsulfonyl; or cholesteryl;

R.sub.11, R.sub.12, R.sub.13, R.sub.14, and R.sub.15 may be the same or different and are each independently hydrogen; C.sub.1-20 alkyl; C.sub.1-20 alkylcarbonyloxy; amino; benzyl; C.sub.1-20 alkoxymethyl; C.sub.1-20 alkylamido; or ##STR4## r is 0 or 1; s is 0 or 1; and t is 0

to 20; provided that s may only be 0 when both r and t are greater than 0 or when r is 0 and R.sub.10 is amino; phenyl; substituted phenyl; 1-adamantyl; or heterocycle selected from the group consisting of 2- or 3-furyl, 2- or 3- thienyl, 2- or 3- pyrrolidinyl, 2-, 3- or 4- pyridyl, and 1-tetrazolyl, said heterocycle optionally substituted with C.sub.1-20 alkylcarbonyl; and where R.sub.3 or R.sub.4 is other than hydrogen, the other of R.sub.3 and R.sub.4 may additionally be C.sub.1-4
alkylcarbonyl;

R.sub.5 is hydrogen or C.sub.1-10 alkyl;

R.sub.6 is hydrogen or R.sub.6 and R.sub.7 taken together are --(CH.sub.2).sub.3 --;

R.sub.7 is hydrogen; C.sub.1-7 alkyl; hydroxymethyl; mercaptomethyl; benzyl; or substituted benzyl;

R.sub.8 and R.sub.9 may be the same or different and are each independently COOR, or CONR'R", where R is hydrogen or C.sub.1-7 alkyl, and R' and R" are hydrogen or C.sub.1-3 alkyl;

when R.sub.5 is C.sub.1-10 alkyl, the stereochemistry at asymmetric center I is D or L;

when R.sub.7 is other than hydrogen, the stereochemistry at asymmetric center II is L; and the stereochemistry at asymmetric center III is D; and acid addition and quaternary salts thereof.

L14 ANSWER 12 OF 12 USPATFULL
AN 81:14980 USPATFULL
TI Immunologically active dipeptidyl saccharides and methods of preparation
IN Durette, Philippe L., New Providence, NJ, United States
Shen, Tsung-Ying, Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4256735 19810317
AI US 1979-7108 19790129 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Phillips, Delbert R.; Assistant Examiner: Hazel, Blondel
LREP Perrella, Donald J., Levitt, Julian S.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1,14
DRWN No Drawings
LN.CNT 1559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;

R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or

substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

Provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

When R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

The stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.